Next-Generation Blood Test (Stockholm3) Improves Detection of Aggressive Prostate Cancer
Key Questions
How does the Stockholm3 test improve prostate cancer detection?
It significantly outperforms PSA in identifying aggressive prostate cancer without increasing unnecessary biopsies. The multi-marker blood test is especially relevant for men over 50.
Is the Stockholm3 test currently available in the US?
The test is not yet FDA-approved but represents a major advance in blood-based cancer diagnostics. It could shift future screening guidelines.
What advantages does Stockholm3 offer over standard PSA testing?
It detects more aggressive cancers earlier while reducing false positives that lead to unneeded procedures. Clinical data support its superior performance in recent studies.
The Stockholm3 multi-marker blood test significantly outperforms PSA in detecting aggressive prostate cancer without increasing unnecessary biopsies. This could shift screening guidelines and is highly relevant for men over 50. The test is not yet FDA-approved but represents a major advance in blood-based cancer diagnostics.